Precipio, Inc. (PRPO) Stock Analysis | Price, Returns, Financials & Key Metrics

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

7.09 k

Shareholding (Mar 2025)

FII

0.04%

Held by 2 FIIs

DII

96.98%

Held by 3 DIIs

Promoter

0.00%

What does Precipio, Inc. do?

22-Jun-2025

Precipio, Inc. is a micro-cap cancer diagnostics company that offers products and services for the oncology market, with recent net sales of $5 million and a net loss of $1 million. The company has a market cap of $16.78 million and operates with a negative return on equity of -26.46%.

Who are in the management team of Precipio, Inc.?

22-Jun-2025

As of March 2022, the management team of Precipio, Inc. includes Dr. Douglas Fisher (Interim Chairman), Mr. Ilan Danieli (CEO), and several directors, including Mr. David Cohen, Mr. Mark Rimer, Dr. Jeffrey Cossman, Ms. Kathleen LaPorte, and Mr. Richard Sandberg. They are responsible for the company's strategic direction and operations.

Is Precipio, Inc. technically bullish or bearish?

25-Jun-2025

As of October 1, 2023, there is insufficient technical data for Precipio, Inc. to determine a bullish or bearish outlook.

Is Precipio, Inc. overvalued or undervalued?

25-Jun-2025

As of October 1, 2023, Precipio, Inc. is fairly valued with a price-to-earnings ratio of 15.2, competitive against peers, and has shown resilient stock performance aligned with market trends.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

With a growth in Net Sales of 14.71%, the company declared Very Positive results in Jun 25

OPERATING CASH FLOW(Y) Highest at USD 0.91 MM
ROCE(HY) Highest at -14.76%
RAW MATERIAL COST(Y) Fallen by -11.47% (YoY)

Increasing Participation by Institutional Investors

Market Beating Performance

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 34 Million (Micro Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-0.05

Return on Equity

-15.82%

Price to Book

2.77

Revenue and Profits:

Net Sales:

6 Million

(Quarterly Results - Jun 2025)

Net Profit:

0 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

55.76%

6 Months

131.71%

1 Year

317.06%

2 Years

260.32%

3 Years

58.39%

4 Years

-30.09%

5 Years

-47.19%

Precipio, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

Precipio, Inc. Hits New 52-Week High of $28.50, Up 345.57%

Precipio, Inc., a microcap in the Pharmaceuticals & Biotechnology sector, achieved a new 52-week high of USD 28.50, reflecting a significant year-over-year performance increase. With a market cap of USD 34 million, the company shows resilience despite being currently loss-making, as indicated by its financial metrics.

Precipio, Inc. Hits New 52-Week High of $27.29, Up 356.52%

Precipio, Inc., a microcap company in the Pharmaceuticals & Biotechnology sector, achieved a new 52-week high of USD 27.29 on November 19, 2025, reflecting a substantial year-over-year gain. Despite its current losses and competitive challenges, the milestone highlights the company's notable market activity and performance.

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

39.64%

EBIT Growth (5y)

11.51%

EBIT to Interest (avg)

-8.41

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.04

Sales to Capital Employed (avg)

1.20

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

13.10%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

1.45

EV to EBIT

-5.49

EV to EBITDA

-11.51

EV to Capital Employed

1.47

EV to Sales

0.82

PEG Ratio

Dividend Yield

ROCE (Latest)

-26.73%

ROE (Latest)

-26.46%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bullish

Mildly Bullish

RSI

No Signal

Bearish

Bollinger Bands

Mildly Bullish

Bullish

Moving Averages

Bullish (Daily)

KST

Mildly Bearish

Dow Theory

No Trend

Mildly Bullish

OBV

No Trend

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Mar 2025

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 3 Schemes (2.99%)

Foreign Institutions

Held by 2 Foreign Institutions (0.04%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 16.33% vs -10.91% in Mar 2025",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 111.11% vs -125.00% in Mar 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "5.70",
          "val2": "4.90",
          "chgp": "16.33%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-0.40",
          "val2": "-0.40",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.10",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "0.10",
          "val2": "-0.90",
          "chgp": "111.11%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-145.70%",
          "val2": "-174.30%",
          "chgp": "2.86%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 21.71% vs 61.70% in Dec 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 27.12% vs 51.64% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "18.50",
          "val2": "15.20",
          "chgp": "21.71%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-2.70",
          "val2": "-6.10",
          "chgp": "55.74%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.10",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "1.70",
          "chgp": "-100.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-4.30",
          "val2": "-5.90",
          "chgp": "27.12%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-227.50%",
          "val2": "-501.40%",
          "chgp": "27.39%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ

Jun'25

Mar'25

Change(%)

Net Sales

5.70

4.90

16.33%

Operating Profit (PBDIT) excl Other Income

-0.40

Interest

0.00

Exceptional Items

0.10

0.00

Consolidate Net Profit

0.10

-0.90

111.11%

Operating Profit Margin (Excl OI)

-145.70%

-174.30%

2.86%

USD in Million.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Jun 2025 is 16.33% vs -10.91% in Mar 2025

Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is 111.11% vs -125.00% in Mar 2025

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

18.50

15.20

21.71%

Operating Profit (PBDIT) excl Other Income

-2.70

-6.10

55.74%

Interest

0.10

0.00

Exceptional Items

0.00

1.70

-100.00%

Consolidate Net Profit

-4.30

-5.90

27.12%

Operating Profit Margin (Excl OI)

-227.50%

-501.40%

27.39%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is 21.71% vs 61.70% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 27.12% vs 51.64% in Dec 2023

All Annual Results

Company CV

About Precipio, Inc.

Precipio, Inc.

Pharmaceuticals & Biotechnology

Precipio, Inc. is a cancer diagnostics company providing diagnostic products and services to the oncology market. The Company’s platform is designed to provide physicians and their patients access to necessary technology in order to provide diagnoses. The Company is focused on developing various technologies including IV-Cell, HemeScreen and ICE-COLD-PCR (ICP). The IV-Cell is a proprietary culture media that addresses the problem of selective culturing-by creating a universal media that enables simultaneous culturing of hematopoietic cell lineages. ICP is a specimen enrichment technology that increases the sensitivity of molecular based tests. The Company has developed a screening panel for genes in one rapid scanning panel, HemeScreen.

Company Coordinates

Company Details

12325 Emmet St , OMAHA NE : 68164-4243

Tel: 1 203 7877888

http://www.precipiodx.com/

Registrar Details

Precipio, Inc.

1Day

52 Week

CASH

FII

DII

Promoter

What does Precipio, Inc. do?

Watch in Real-Time

Who are in the management team of Precipio, Inc.?

Is Precipio, Inc. technically bullish or bearish?

Is Precipio, Inc. overvalued or undervalued?

MarketsMojo — Loved in India, Now Global

Dashboard

With a growth in Net Sales of 14.71%, the company declared Very Positive results in Jun 25

Increasing Participation by Institutional Investors

Market Beating Performance

Mojo Parameters

Stock DNA

Total Returns (Price + Dividend)

Risk Adjusted Returns v/s

News

Precipio, Inc. Hits New 52-Week High of $28.50, Up 345.57%

Precipio, Inc. Hits New 52-Week High of $27.29, Up 356.52%

Announcements

Corporate Actions

Quality key factors

Valuation key factors

Technicals key factors

Shareholding Snapshot : Mar 2025

Shareholding Compare (%holding)

Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ

Annual Results Snapshot (Consolidated) - Dec'24

About Precipio, Inc.

Company Coordinates